A National Survey of United States-Based Endocrinologists Who Prescribe Gender-Affirming Hormone Therapy

被引:2
|
作者
Bisno, Daniel I. [1 ]
Lubitz, Sara [2 ,3 ]
Marshall, Ian [3 ,4 ]
Cohen, David A. [2 ,3 ,5 ]
机构
[1] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA
[2] Rutgers Robert Wood Johnson Med Sch, Dept Med, Div Endocrinol Metab & Nutr, New Brunswick, NJ USA
[3] Rutgers Robert Wood Johnson Univ Hosp, PROUD Gender Ctr New Jersey, New Brunswick, NJ USA
[4] Rutgers Robert Wood Johnson Med Sch, Dept Pediat, Div Pediat Endocrinol, New Brunswick, NJ USA
[5] Educ,125 Patterson St CAB 7308, New Brunswick, NJ 08901 USA
关键词
transgender; LGBTQ; gender -affirming hormone therapy; Introduction; INFORMED-CONSENT MODEL; HEALTH-CARE; TRANSGENDER HEALTH; IDENTITY; BARRIERS;
D O I
10.1016/j.eprac.2023.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The World Professional Association for Transgender Health Standards of Care Version 7 recommended that before initiating gender-affirming hormone therapy (GAHT), patients should seek a psychosocial evaluation from a mental health professional documenting a diagnosis of persistent gender dysphoria. The Endocrine Society published guidelines in 2017 recommending against an obligatory psychosocial evaluation, which was affirmed in the recently published World Professional Association for Transgender Health Standards of Care Version 8 from 2022. Little is known about how endocrinologists ensure appropriate psychosocial assessment for their patients. This study assessed the protocols and characteristics of U.S.-based adult endocrinology clinics that prescribe GAHT.Methods: An anonymous electronic survey sent to members of a professional organization and the "Endocrinologists" Facebook group was responded by 91 practicing board-certified adult endocrinologists who prescribe GAHT.Results: Thirty-one states were represented by the respondents. Overall, 83.1% of GAHT-prescribing endocrinologists reported accepting Medicaid. They reported working in university practices (28.4%), community practices (22.7%), private practices (27.3%), and other practice settings (21.6%). Overall, 42.9% of the respondents reported that their practice required documentation of a psychosocial evaluation from a mental health professional before initiating GAHT.Conclusion: Endocrinologists who prescribe GAHT are divided about requiring a baseline psychosocial evaluation before prescribing GAHT. Further work is needed to understand the impact of psychosocial assessment on patient care and facilitate the uptake of new guidelines into clinical practice.& COPY; 2023 AACE. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:465 / 470
页数:6
相关论文
共 50 条
  • [41] Adult Height in Transgender Youth Who Receive GnRH Analogues Followed by Gender-Affirming Hormone Therapy
    Cheung, Ada S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 110 (02): : e538 - e539
  • [42] Gallbladder disease in transgender individuals: associations with gender-affirming hormone therapy
    Tabernacki, Tomasz
    Loria, Matthew
    Rhodes, Stephen
    Pope, Rachel
    Gupta, Shubham
    Banik, Swagata
    Mishra, Kirtishri
    INTERNATIONAL JOURNAL OF TRANSGENDER HEALTH, 2024, 25 (04) : 896 - 910
  • [43] The return of spermatogenesis in transgender women ceasing gender-affirming hormone therapy
    Yau, Mabel
    Safer, Joshua D.
    CELL REPORTS MEDICINE, 2023, 4 (01)
  • [44] Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents
    Millington, Kate
    Lee, Janet Y.
    Olson-Kennedy, Johanna
    Garofalo, Robert
    Rosenthal, Stephen M.
    Chan, Yee-Ming
    PEDIATRICS, 2024, 153 (05)
  • [45] Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy
    Mullins, Eric S.
    Geer, Rebecca
    Metcalf, Megan
    Piccola, Jeanne
    Lane, Adam
    Conard, Lee Ann E.
    Mullins, Tanya L. Kowalczyk
    PEDIATRICS, 2021, 147 (04)
  • [46] Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons Comment
    Tangpricha, Vin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (06): : E2632 - E2633
  • [47] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Michihiro Satoh
    Hypertension Research, 2023, 46 : 792 - 793
  • [48] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Satoh, Michihiro
    HYPERTENSION RESEARCH, 2023, 46 (03) : 792 - 793
  • [49] Gender-Affirming Hormone Therapy: Physical and Sociopsychological Effects, Impact and Satisfaction
    Santos, Rafael B.
    Lemos, Carolina
    Saraiva, Miguel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [50] Barriers and Facilitators to Gender-affirming Hormone Therapy in the Veterans Health Administration
    Wolfe, Hill L.
    Boyer, Taylor L.
    Shipherd, Jillian C.
    Kauth, Michael R.
    Jasuja, Guneet K.
    Blosnich, John R.
    ANNALS OF BEHAVIORAL MEDICINE, 2023, 57 (12) : 1014 - 1023